On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Based in Bad Homburg, Germany, Fresenius Medical Care AG & Co. KGaA is one of the largest integrated providers of ...

JD.com, Universal Health Services, Fresenius Medical Care and Qifu Technology are part of the Zacks Screen of the Week article.

Fresenius SE FRE0.03%increase; green up pointing triangle said it raised around 1.1 billion euros ($1.15 billion) after selling part of its Fresenius Medical Care FME 0.88%increase; green up ...

The primary driver behind last 12 months revenue was the Fresenius Helios segment contributing a total revenue of €12.7b (58% of total revenue). Notably, cost of sales worth €16.5b amounted to 75% of ...

Zacks Research boosted their Q1 2025 EPS estimates for shares of Fresenius Medical Care in a report released on Tuesday, ...

Fresenius SE raised close to €1.1 billion ($1.2 billion) in a sale of shares in Fresenius Medical Care AG as well as exchangeable bonds linked to the dialysis firm, as it looks to cut debt and ...

March 4 (Reuters) - Dialysis firm Fresenius Medical Care (FMEG.DE), opens new tab shares fell 7.8% after German healthcare group Fresenius SE (FREG.DE), opens new tab sold part of its stake in the ...

In a report released today, Graham Doyle from UBS maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research Report), with a price ...